Bush Administration Nominates von Eschenbach to Head FDA - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Bush Administration Nominates von Eschenbach to Head FDA


ePT--the Electronic Newsletter of Pharmaceutical Technology

Bush Administration Nominates von Eschenbach to head FDA

The Ides of March brought good news to US Food and Drug Administration (Rockville, MD, www.fda.gov) Acting Commissioner Andrew von Eschenbach. The White House announced his nomination to the job on a permanent basis. Von Eschenbach has been the acting head of FDA since former commissioner Lester Crawford resigned in September 2005. As acting head, von Eschenbach’s decision to keep his job as chief of the National Cancer Institute has raised criticism and conflict-of-interest concerns; if confirmed he will have to drop his other hat.

Although he has strong support from pharma and other industries regulated by FDA, von Eschenbach will face a tough confirmation process in the Senate. FDA’s delayed action on approving an OTC version of the morning-after pill Plan B once again is likely to dominate the discussion, along with safety concerns about drugs and medical devices.
White House staffers evidently interviewed a number of outside candidates, but had difficulty finding someone with equally strong medical and research credentials who is familiar with FDA regulatory issues and meets administration political criteria. Everyone agrees that FDA needs a permanent leader, but getting there will not be that easy. 

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
33%
Breakthrough designations
17%
Protecting the supply chain
50%
Expedited reviews of drug submissions
0%
More stakeholder involvement
0%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here